The pharma giant Pfizer announced to continue investigating the data manipulations committed by their former cancer researcher Min-Jean Yin, retractions of two more publications were requested and yet another paper’s fate is being currently decided. Again it is about studies of pharmacological inhibitors of cancer molecular pathways which Yin’s former lab at the Pfizer California research site has faked. These two retraction requests come is addition to 5 Yin retractions which Pfizer already announced on my site in October 2016 and which meanwhile happened. The PubPeer-listed evidence was first presented on my site in May 2016. Back then, the reader of my site, who posted that evidence of duplicated western blots on PubPeer and alerted me to it, preferred to remain unnamed. Now however, she agreed to be named: it was the microbiologist, image integrity specialist and host of the successful public outreach blog Microbiome Digest, Elisabeth Bik. She now forwarded to me this message: Continue reading “Pfizer announces more retractions for sacked lab head Min-Jean Yin, whistleblower revealed”
Tag: retraction
Bioethicist Arthur Caplan calls for retraction of all Macchiarini papers
Arthur Caplan, internationally respected professor of bioethics and director of the Division of Medical Ethics at the New York University, requested publicly retractions of the bioethics reviews on regenerative medicine he co-authored with the scandal surgeon Paolo Macchiarini. Caplan notified the journals with his retraction requests, but said to have received no response from them yet. Not only this: Caplan calls for all works of Macchiarini to be retracted.
Macchiarini is now an international pariah, he recently again lost his job, this time with the Kazan Federal University in Russia (see my report). His publications are under investigation at his former workplace the Karolinska Institutet in Stockholm (where he was previously sacked), the Swedish state announced to soon charge him with manslaughter, due to 3 lethal plastic trachea transplants he performed at Karolinska. Continue reading “Bioethicist Arthur Caplan calls for retraction of all Macchiarini papers”
COPE, the publishers’ Trojan horse, calls to abolish retractions
Four private scientists without any agenda whatsoever published a research result preprint on the portal BioRxiv. The “new results” reported in the article are actually new ideas which are just as good as any research results, because they are supposed to bring the field of scholarly communication forward. The question is, where to, and why should anyone go there. Because the idea is to abolish the only tool science now has at hand to punish research misconduct: retractions. Fraudulent papers are to receive instead an amendment, which will notify those particularly inclined readers that research data or ethics approval (for clinical studies) might have been falsified or missing. Those proposing to remove the only punitive measure available in scholarly publishing are in fact the very people who are supposed to be overseeing the editorial integrity. The goats whom science welcomed as gardeners now dropped the pretence and declared their true vision for the garden. Continue reading “COPE, the publishers’ Trojan horse, calls to abolish retractions”
Retraction, and another looming misconduct finding for Macchiarini and Jungebluth
The misconduct-tainted paper on oesophagus transplants in rats (Sjöqvist et al 2014) by the fallen star of regenerative medicine Paolo Macchiarini is finally retracted by the journal Nature Communications. This happens after Swedish investigations found the authors (primarily the scandal thorax surgeon and his right-hand man Philipp Jungebluth) guilty of data manipulation and research misconduct in September 2016 and after the Karolinska Institutet (KI) shortly before Christmas publicly demanded a retraction (see my report here). Today’s retraction is a major setback for Macchiarini, since his current employment and funding at the Federal University of Kazan (KFU) in Russia depend on his experiments with oesophageal transplants in primates (see my reports here and here). That Russian project was in turn only possible because of Macchiarini’s allegedly successful experiments in rats, published in a prestige journal with “Nature” in its title. This paper’s retraction is therefore probably only the beginning of a whole looming avalanche of bad news for Macchiarini and his acolyte Jungebluth (who currently sues me in court). An expert review of their publication Jungebluth et al 2015 declares the findings of misconduct, ethics breach and patient abuse. The report however has yet to be confirmed by a commission at the Swedish Central Ethics Review Board (CEPN) and then formulated as an official decree by the KI. I publish the expert reviewer report below. Continue reading “Retraction, and another looming misconduct finding for Macchiarini and Jungebluth”
Three retractions and lost court case for zombie Susana Gonzalez
The Spanish zombie scientist Susana González, former star of regenerative medicine and ageing research, now retracts two papers in Nature Communications, after she only recently retracted a paper in Cell Cycle. The responsibility for the absence of original data and data manipulations is with her. She also recently lost her court case against her sacking with the Centro Nacional de Investigaciones Cardiovasculares (CNIC) in Madrid, though this may go into the next court instance. Her ERC research grant of €2 Million remains suspended. I previously reported about this and Gonzalez’s data integrity issues as well as her sacking from CNIC, and later on about her new job with Centro de Biología Molecular Severo Ochoa (CBMSO), also in Madrid. It seems at the present stage, Gonzalez is out on her ear of doing research, but certainly not out of being employed in academic research in Spain. Continue reading “Three retractions and lost court case for zombie Susana Gonzalez”
Voinnet retraction brings entire school of thought crashing down
Another retraction hits the fallen star plant scientist Olivier Voinnet. This time it is a previously corrected paper in Science, which was pulled after new evidence of further data manipulations appeared on PubPeer some months after its 3rd correction.
This makes it Voinnet’s 8th retraction, but the loss of the Dunoyer et al 2010 paper is more than just another brick falling from his great publishing record edifice. It is one of the two pillars of an entire school of thought in the field of plant pathogen defence, which we now witness crumbling into dust (see my earlier report and a brief summary below).
The Dunoyer et al 2010 paper has been corrected twice before (both are behind paywall, the one from April 15th 2011 acknowledges image reuse: “The image in Fig. 3B (center panel) was previously published as Fig. 1e in P. Dunoyer et al., Nat. Genet. 39, 848 (2007)”). The third correction from January 22nd 2016 declared a shopping list of further image irregularities, with Patrice Dunoyer taking full responsibility, just like he did on many other occasions (see my earlier report here).
Continue reading “Voinnet retraction brings entire school of thought crashing down”
5 retractions and a sack for Pfizer lead cancer researcher Min-Jean Yin
Five months ago, I reported about data integrity concerns in 6 publications authored by Min-Jean Yin, who had been working at the pharma giant Pfizer in La Jolla, California, as Senior Principal Scientist since 2003. One paper, where she contributed as a collaborator (Lamoureux et al, European Urology, 2014), has been corrected already in March 2016. Five other cancer research papers, on the efficiency of Pfizer’s own pharmacological enzyme inhibitors, will now be retracted, after an investigation performed by Pfizer confirmed the suspicions of data manipulation, originally raised on PubPeer. These five papers stemmed directly from the Pfizer lab which Yin used to be in charge of. Used to be – because according to her recently updated LinkedIn profile, Yin doesn’t work there anymore. Since September 2016, she joined a rather unremarkable Californian biotech start-up Diagnologix LLC in San Diego, as “General Manager”. With such a career (and surely also salary) setback, it is safe to assume Yin did not leave Pfizer after 13 years of service entirely voluntarily. Continue reading “5 retractions and a sack for Pfizer lead cancer researcher Min-Jean Yin”
